


PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/706,595
				Filing Date	November 12, 2003
				Confirmation Number	Unknown
				First Named Inventor	South et al.
				Group Art Unit	Unknown 1621
				Examiner Name	Unknown S. Kumar
Sheet	1	of	6	Attorney Docket No.	PHA 4163.5 (3455/1)



U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
8/c	1	4,489,096	B1	Terao et al.	12-18-1984
	2	4,851,413	B1	Terao et al.	07-25-1989
	3	4,992,469	B1	Ozawa et al.	02-12-1991
	4	5,008,267	B1	Katakami, et al.	04-16-1991
	5	5,304,658	B1	Terao et al.	04-19-1994
	6	5,441,960	B1	Bernstein et al.	08-15-1995
	7	5,656,645	B1	Tamura et al.	08-12-1997
	8	5,658,930	B1	Tamura et al.	08-19-1997
	9	5,668,289	B1	Sanderson et al.	09-16-1997
	10	5,718,819 5741819	B1	Illig et al.	04-12-1998
	11	5,792,779	B1	Sanderson et al.	08-11-1998
	12	5,861,380	B1	Gyorkos et al.	01-19-1999
	13	5,866,573	B1	Sanderson et al.	02-02-1999
	14	5,869,487	B1	Coburn et al.	02-09-1999
	15	5,872,138	B1	Naylor-Olsen et al.	02-16-1999
Examiner Signature	S. Kumar		Date Considered	9/23/04	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/706,595
				Filing Date	November 12, 2003
				Confirmation Number	Unknown
				First Named Inventor	South et al.
				Group Art Unit	Unknown 1621
				Examiner Name	Unknown S. Kumar
Sheet	2	of	6	Attorney Docket No.	PHA 4163.5 (3455/1)

8e	16	6,011,158	B1	Tamura et al.	01-04-2000
	17	6,037,356	B1	Lu et al.	03-14-2000
20	18	6,180,627	B1	Blagg et al.	01-30-2001

FOREIGN PATENT DOCUMENTS

Examiner Initials*		Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
8e	19	DE	198 51 421	A1	Boehringer Ingelheim Pharma KG	05-11-2000	
	20	EP	354 495	A1	Godecke Aktiengesellschaft	02-14-1990	
	21	EP	528 633	B1	Zeneca Limited	02-24-1993	
	22	EP	826 671	A1	The Green Cross Corporation	03-04-1998	
	23	EP	936 216	A1	Nippon Kayaku Kabushiki Kaisha	08-18-1999	
	24	EP	940 400	A1	Yoshitomi Pharmaceutical Industries, Ltd.	09-08-1999	
	25	EP	997 474	A1	Pfizer Inc	05-03-2000	
	26	WO	93/21214	A1	Zeneca Limited	10-28-1993	
	27	WO	96/18644	A1	Corvas International Inc.	06-20-1996	
28	28	WO	96/33974	A1	The Green Cross Corporation (abstract)	10-31-1996	

Examiner Signature	S. Kumar	Date Considered	9/23/04
--------------------	----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/706,595
				Filing Date	November 12, 2003
				Confirmation Number	Unknown
				First Named Inventor	South et al.
				Group Art Unit	Unknown 1621
Examiner Name	Unknown S. Kumar				
Sheet	3	of	6	Attorney Docket No.	PHA 4163.5 (3455/1)

29	WO	96/39380	A1	3-Dimensional Pharmaceuticals, Inc.	12-12-1996
30	WO	96/40100	A1	3-Dimensional Pharmaceuticals, Inc.	12-19-1996
31	WO	97/01338	A1	Merck & Co., Inc.	01-16-1997
32	WO	97/30708	A1	Merck & Co., Inc.	08-28-1997
33	WO	97/40024	A1	Merck & Co., Inc.	10-30-1997
34	WO	97/46207	A2	Corvas International Inc.	12-11-1997
35	WO	98/08840	A1	Merck & Co., Inc.	03-05-1998
36	WO	98/09949	A1	Nippon Kayaku Kabushiki Kaisha (abstract)	03-12-1998
37	WO	98/09987	A1	Biochem Pharma, Inc.	03-12-1998
38	WO	98/10763	A1	Merck & Co., Inc.	03-19-1998
39	WO	98/16525	A1	Cor Therapeutics, Inc.	04-23-1998
40	WO	98/16547	A1	Cor Therapeutics, Inc.	04-23-1998
41	WO	97/17274	A1	Merck & Co., Inc.	04-30-1998
42	WO	98/31670	A1	Merck & Co., Inc.	07-23-1998
43	WO	98/42342	A1	Merck & Co., Inc.	10-01-1998
44	WO	98/47876	A1	Akzo Nobel N.V.	10-29-1998
45	WO	98/50420	A1	Akzo Nobel N.V.	11-12-1998
46	WO	99/00121	A1	Eli Lilly and Company	01-07-1999

Examiner Signature	S. Kumar	Date Considered	9/23/04
--------------------	----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/706,595
				Filing Date	November 12, 2003
				Confirmation Number	Unknown
				First Named Inventor	South et al.
				Group Art Unit	Unknown 1621
				Examiner Name	Unknown S. Kumer
Sheet	4	of	6	Attorney Docket No.	PHA 4163.5 (3455/1)

54	47	WO	99/00126	A1	Eli Lilly and Company	01-07-1999	
	48	WO	99/00128	A1	Eli Lilly and Company	01-07-1999	
	49	WO	99/11267	A1	Merck & Co., Inc.	03-11-1999	
	50	WO	99/26920	A1	Corvas Interantional, Inc.	06-03-1999	
	51	WO	99/26926	A1	3-Dimensional Pharmaceuticals, Inc.	06-03-1999	
	52	WO	99/36426	A1	Warner-Lambert Company	07-22-1999	
	53	WO	99/43660	A1	Neurogen Corporation	09-02-1999	
	54	WO	99/48892	A1	Merck & Sharp & Dohme Limited	09-30-1999	
	55	WO	99/59591	A1	Merck & Co., Inc.	11-25-1999	
	56	WO	99/61442	A1	Merck & Co., Inc.	12-02-1999	
	57	WO	99/62538	A1	Cortech Inc.	12-09-1999	
	58	WO	99/64446	A1	3-Dimensional Pharmaceuticals, Inc.	12-16-1999	
	59	WO	00/18762	A1	Merck & Co., Inc.	04-06-2000	
	60	WO	00/26210	A1	Merck & Co., Inc.	05-11-2000	
	61	WO	00/26211	A1	Merck & Co., Inc.	05-11-2000	
	62	WO	00/32574	A1	Sanofi-Synthelabo (abstract)	06-08-2000	
	63	WO	00/39102	A1	Du Pont Pharmaceuticals Company	07-06-2000	
64	64	WO	00/69826	A1	Monsanto Company	11-23-2000	

Examiner Signature	S. Kumer	Date Considered	9/23/04
--------------------	----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/706,595
				Filing Date	November 12, 2003
				Confirmation Number	Unknown
				First Named Inventor	South et al.
				Group Art Unit	Unknown 1621
				Examiner Name	Unknown S. Kumar
Sheet	5	of	6	Attorney Docket No.	PHA 4163.5 (3455/1)

65	WO	00/69832	A1	Monsanto Company	11-23-2000
66	WO	00/69833	A1	Monsanto Company	11-23-2000

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
gle	67	COBURN, C.A., "Small-molecule direct thrombin inhibitors 1997-2000." Expert Opinions on Therapeutic Patents, 2001, 721-738, Vol. 11, No. 5.	
	68	HANDIN, R., "Bleeding and Thrombosis." Harrison's Principles of Internal Medicine, 12th Edition, 1991, pp. 348-353, McGraw-Hill, Inc., New York.	
	69	KOHAMA et al. Chemical Abstracts, vol. 124, no. 9, 1996, Abstract No. 117979w, "Preparation of piperidinylxyacetylaminobenzoylalanine derivatives and analogs as antithrombotics." p 1337, XP002172033.	
	70	LJUNGBERG, K.B. et al., Computational Modelling of Inhibitor Binding to Human Thrombin, European Journal of Pharmaceutical Sciences, (2001), pp. 441-446, Vol. 12.	
	71	MAJERUS et al. "Anticoagulant, Thrombolytic, and Antiplatelet Drugs." Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, 1996, pp. 1341-1359, McGraw-Hill, New York.	
	72	PATEL et al., "Directed Aminomethylation of 3-Hydroxy-3(1H)-pyridinones and 3-hydroxy-4(1H)-pyridinones: Synthesis of iso-Deferiprone." Tetrahedron, 1996, pp. 1835-1840, Vol. 52, No. 5.	
	73	RAUCH, et al., Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences, Annals of Internal Medicine, 2001, pp. 224-233, Vol. 134 - No. 3.	
se	74	SANDERSON et al., "L-373,890, An Achiral, Noncovalent, Subnanomolar Thrombin Inhibitor." Bioorganic & Medicinal Chemistry Letters, Vol. 7, No. 12, pp. 1497-1500, 1997.	

Examiner Signature	S. Kumar	Date Considered	9/23/04
--------------------	----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/706,595
				Filing Date	November 12, 2003
				Confirmation Number	Unknown
				First Named Inventor	South et al.
				Group Art Unit	Unknown 1621
				Examiner Name	Unknown S. Kumar
Sheet	6	of	6	Attorney Docket No.	PHA 4163.5 (3455/1)

80	75	TULINSKY et al., "Novel Asymmetric Synthesis of Atropisomeric 6-Aryl Pyrazinones via an Unusual Chirality Transfer Process." J. Org. Chem., 1999, pp. 93-100, Vol. 64, No. 1.	
	76	VAN AKEN, et al., Anticoagulation: The Present and Future, Clin. Appl. Thrombosis/Hemostasis, 2001, pp. 195-204, Vol. 7 - No. 3.	
	77	XP-002187583 - MOERNER, Hoppe-Seyler's Z. Physiol. Chem., 69, 1910; 357.	
	78	XP-002182132 - DARVAS, et al., "Investigation of the Common Mechanism of Action of Antibacterial Compounds Containing .gamma.-pyridone-.beta.-carboxylic acid Structure by Principal Component." Arzneim.-Forsch., 1979, pp. 1334-1339, Vol. 29, 9.	
81	79	XP-002182410 - TRE COURT et al., "First Synthesis of (+)-harzianopyridone by Metalation of Polysubstituted O-pyridylcarbamates." J. Heterocycl. Chem., 1995, pp. 1117-1114, Vol. 32, No. 4.	

Examiner Signature	S. Kumar	Date Considered	9/23/04
--------------------	----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.